• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Lymphocyte antigen 86 (LY86)

ACP01022

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP01022 Target NameLY86
FormLiquid or Lyophilized powderExpression SystemE.coli
Expression Range21-162aaMol Weight28.6 kDa
Protein LengthFull Length of Mature ProteinPurityGreater than 90% as determined by SDS-PAGE.
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDO95711
Background Information
  • Uniprot Id

    O95711

  • Target Species

    Human

  • Target Name

    LY86

  • Target Full Name

    Lymphocyte antigen 86

  • Target Function

    May cooperate with CD180 and TLR4 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) and cytokine production. Important for efficient CD180 cell surface expression.

  • Target Subcellular Location

    Secreted, extracellular space. Note=Associated with CD180 at the cell surface.

  • Target Tissue Specificity

    Highly expressed in B-cells, monocytes and tonsil.

  • Target Research Area

    Immunology

  • Target Synonyms

    BPAD; dJ80N2.1; Ly 86; Ly-86; Ly86; LY86_HUMAN; Lymphocyte antigen 86; Lymphocyte antigen 86 precursor; Major affective disorder 1; MD 1; MD-1; MD1 protein; MD1 RP105 associated ; MMD 1; MMD-1; Protein MD 1; Protein MD-1; RP1-80N2.1

  • Target Background

    Acts upstream of or within positive regulation of lipopolysaccharide-mediated signaling pathway. Predicted to be located in extracellular space.

Inquire Recombinant Human Lymphocyte antigen 86 (LY86) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification